Sudarshan Pharma Board to Meet Oct 29 for Q2 Results and Fund Raising Proposal

Key numbers

Market Cap	₹756.87 CrSmall Cap
Revenue TTM	₹732.21 CrOperating Revenue
Promoter Holding	57.81%Promoter Stake
Day RSI	28.54Oversold Zone

Key highlights

• Board meeting scheduled for October 29, 2026, to approve Q2 and H1 FY27 financial results
• Capital raising proposal involves equity shares, convertible securities, warrants, or debt instruments
• Fund raising may be executed via Private Placement, Preferential Issue, or Qualified Institutions Placement
• Trading window remains closed for insiders until 48 hours after the results declaration
• Meeting follows the company's approved migration to the NSE Main Board effective October 27, 2026

Dual Agenda: Financial Review and Capital Strategy

Sudarshan Pharma Industries Ltd has officially notified the stock exchanges regarding its upcoming Board of Directors meeting on October 29, 2026. The primary focus of the session is the consideration and approval of the unaudited standalone and consolidated financial results for the quarter and half-year period ending September 30, 2026. In addition to the earnings review, the board will deliberate on a comprehensive fund-raising proposal.

This strategic move aims to strengthen the company's balance sheet through the issuance of diverse financial instruments, potentially including equity shares or convertible warrants. All proposed funding actions remain subject to necessary statutory and regulatory clearances.

Proposed Instruments for Fund Mobilisation

• Issuance of equity shares or convertible securities of any description
• Allocation of warrants or debt securities through Private Placement routes
• Consideration of Preferential Issues or Qualified Institutions Placements (QIP)
• Approval of ancillary actions required for the mentioned fund-raising methods
• Statutory and regulatory approvals required for finalized funding combinations

Strategic Context and Operational Expansion

The upcoming board meeting follows a series of significant corporate developments for Sudarshan Pharma. The company successfully migrated from the BSE SME platform to the NSE Main Board, with listing effective from October 27, 2026. This transition follows an active period of expansion, including an August 2026 MoU to acquire a 76% stake in an API manufacturing facility in Visakhapatnam.

Furthermore, the company bolstered its liquidity in May 2026 through the allotment of USD 10 million in 8% senior unsecured Foreign Currency Convertible Bonds. These initiatives indicate a consistent drive toward scaling its specialty chemicals and API manufacturing footprint.

Recent Financial Performance and Market Status

Sudarshan Pharma entered the current quarter with an operating revenue of ₹174.42 crore for the period ended June 30, 2026, marking a 20.07% year-on-year increase. While its net profit of ₹5.36 crore for the same period showed a 35.5% annual growth, it reflected a sequential decline of nearly 50% from the preceding quarter. The company maintains a market capitalization of ₹756.87 crore and a steady promoter holding of 57.81%.

Investors will closely monitor the October 29 results for signs of margin recovery and specific details regarding the quantum of the proposed capital raise.

What to watch next

• Migration to the NSE Main Board effective October 27, 2026
• Official declaration of Q2 and H1 FY27 financial results on October 29, 2026
• Detailed announcement regarding the approved fund-raising amount and instruments
• Reopening of the trading window for company insiders after the 48-hour cooling period

Sudarshan Pharma Industries · financial snapshot

Share price	₹31.45
Market capitalisation	₹756.87 Cr
Revenue (annual)	₹703.06 Cr
Net profit (annual)	₹23.30 Cr
Revenue (latest quarter)	₹174.42 Cr-21.05% vs previous quarter
Net profit (latest quarter)	₹5.36 Cr-49.99% vs previous quarter
P/E (TTM)	32.48×Sector 34.44×
Promoter holding	57.81%-1.12% QoQ
FII holding	21.94%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.